Italian JAKi study, 685 pts Rx w/ BARI (48%), TOFA (31%), UPA (14%), filgotinib (7%), had half (47%) Rx JAKi as 1st line
Tweet Content
Italian JAKi study, 685 pts Rx w/ BARI (48%), TOFA (31%), UPA (14%), filgotinib (7%), had half (47%) Rx JAKi as 1st line, prior to a biologic. AE of special interest (1137 PYs FU) in 18%, including 1 CVA, 3 deaths/infx. High CV risk pts = Hi AESI(23%) https://t.co/0NN60tvokZ https://t.co/Dzc7OG9Mmv
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off